RecruitingNCT04579120

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

Sponsor

Tammie L. S. Benzinger, MD, PhD

Enrollment

650 participants

Start Date

Sep 1, 2021

Study Type

OBSERVATIONAL

Conditions

Alzheimer Disease

Summary

To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses specialized PET and MRI brain scans to study how tau protein (linked to Alzheimer's disease) and other brain changes relate to aging and dementia. It is part of a broader research program at Washington University's Alzheimer's Disease Research Center. **You may be eligible if...** - You are 18 years old or older - You are already participating in a study affiliated with the Knight Alzheimer's Disease Research Center (ADRC) at Washington University - You have either normal thinking and memory or are in an early stage of Alzheimer's disease - You are able to undergo PET and MRI scans and provide informed consent **You may NOT be eligible if...** - You have a sensitivity to the imaging agents used (AV-1451 or PIB) - You cannot undergo MRI (e.g., pacemaker, metal implants, severe claustrophobia) - You are pregnant or breastfeeding - You have participated in another drug or device clinical trial in the past 30 days - You have had significant radiation exposure from research studies in the past year Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[11C]-Pittsburgh Compound B ([11C]PiB)

A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.

DRUGF 18 AV-1451 (Flortaucipir)

A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).

Locations(1)

Washington University School of Medicine

St Louis, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04579120

Related Trials

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

NCT0684732135 locations

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787288 locations

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

NCT07011745140 locations

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

NCT07011732157 locations

Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

NCT049027031 location